Event-Driven Stocks

Hemab Therapeutics Holdings, Inc.

COAGNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗

Financials

SEC XBRL · annual

No structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
6 acquisitions0 disposals3 open-market buy(s)net +7.8M shares · last 6
InsiderDateTypeSharesPrice
Ra Capital Management, L.P.10% ownerMay 19, 2026Buy3,802$24.97
Ra Capital Management, L.P.10% ownerMay 12, 2026Buy6,387$24.90
Ra Capital Management, L.P.10% ownerMay 7, 2026Buy7,921$24.34
Ra Capital Management, L.P.DirectorMay 4, 2026Conversion3.6M—
Novo Holdings A/S10% ownerMay 4, 2026Conversion4.2M—
Maraganore JohnDirectorMay 4, 2026Conversion17,974—

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026758,6971.2+100.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)